Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- Drug: Chidamide, Rituximab, Gemcitabine,Oxaliplatin
- Registration Number
- NCT04022005
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the treatment of transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
- biopsy proved CD20+ DLBCL;
- relapse or refractory DLBCL#
- previously received systemic chemotherapy with anthracycline#
- not eligible for autologous hematopoietic stem cell transplantation#
- at least one evaluable lesion#
- ECOG PS 0-1;
- 18-75 years; without other malignancy;
- proper functioning of the major organs.
- double-hit lymphoma;
- previously received treatment of HDAC inhibitor;
- plan to receive autologous stem cell transplantation;
- involvement of central nervous system;
- previously received gemcitabine within the past 6 months;
- patients who received treatment for hematologic toxicity caused by previous chemotherapy within 7 days before enrollment;
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Chidamide combined with R-GemOx Chidamide, Rituximab, Gemcitabine,Oxaliplatin Chidamide, 20 mg,twice per week; Rituximab 375mg/m2, d1, intravenous drip; Gemcitabine 1000mg/m2, d2, intravenous drip; Oxaliplatin 100mg/m2, d2,intravenous drip; All patients received up to 6 treatment cycles of 21 days. Patients with CR or PR will receive chidamide maintenance therapy.
- Primary Outcome Measures
Name Time Method ORR 4-years the proportion of patients who had CR, and PR according to the revised 2014 Lugano criteria for response assessment of lymphoma.
- Secondary Outcome Measures
Name Time Method PFS 4-years the time from the date of enrollment until either PD or death.
OS 4-years the time from the date of enrollment until death
DOR 4-years the time from the first CR or PR to the first documented progressive disease (PD) or death, whichever occurred earlier.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University🇨🇳Guangzhou, Guangdong, China